BeaconEquity.com announces the publication of an article covering the 2008 financial results of Immunosyn.
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m
In the article the author writes:
“Immunosyn Corp. (OTCBB: IMYN), a biotechnology company with exclusive worldwide marketing, sales and distribution rights, recently announced its financial results for the fiscal year ended December 31, 2008. … For fiscal year 2008, the La Jolla, Calif.-based company reports $1,045,013 in sales and general administrative expenses (SG&A), compared with $647,000 for last fiscal year. The company incurred $61,326 in interest expenses, up from $26,000 for the same period last year. Net loss of $1,106,339 was recorded for the fiscal year ended December 31, 2008, compared with $672,837 for the same period last year.”
“Striving for financial efficiency,’’ states Immunosyn’s CEO:
‘“We were able to control costs in 2008 and appreciated the advances from affiliates,’ Stephen Ferrone, Immunosyn’s CEO stated in the press release. ‘We are striving for financial efficiency in the execution of marketing and distribution strategy when approvals for SF-1019 are obtained by Argyll Biotechnologies LLC.’”
To read the entire article visit http://www.beaconequity.com/m
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
